Obalon Therptcs (NASDAQ: OBLN) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Obalon Therptcs to related companies based on the strength of its analyst recommendations, profitability, risk, dividends, valuation, earnings and institutional ownership.
Institutional and Insider Ownership
44.1% of Obalon Therptcs shares are held by institutional investors. Comparatively, 54.9% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 16.4% of Obalon Therptcs shares are held by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Obalon Therptcs and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Obalon Therptcs||$3.39 million||-$20.46 million||-4.14|
|Obalon Therptcs Competitors||$1.67 billion||$207.58 million||74.93|
Obalon Therptcs’ peers have higher revenue and earnings than Obalon Therptcs. Obalon Therptcs is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings for Obalon Therptcs and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Obalon Therptcs Competitors||109||728||1025||10||2.50|
Obalon Therptcs currently has a consensus price target of $12.00, suggesting a potential upside of 45.81%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.44%. Given Obalon Therptcs’ higher possible upside, equities analysts clearly believe Obalon Therptcs is more favorable than its peers.
This table compares Obalon Therptcs and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Obalon Therptcs Competitors||-101.23%||-92.70%||-30.32%|
Obalon Therptcs peers beat Obalon Therptcs on 7 of the 11 factors compared.
About Obalon Therptcs
Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with MarketBeat.com's FREE daily email newsletter.